Makrolid antibiotikumok immunmodulátor és myelomaellenes hatásai

Translated title of the contribution: Immunomodulatory and anti-myeloma effects of macrolide antibiotics

Mikala Gábor, Jákó János, Vályi Nagy István

Research output: Contribution to journalArticle


Systemic administration of macrolide antibiotics results in intracellular accumulation of the compounds that may modulate various cellular functions. The immunomodulatory effects may be significant among the non-antimicrobial activities and be of pronounced importance in certain disease states. Alteration of phospholipid metabolism as well as modulation of NF-κB activity participate in the immunomodulatory effects: secretion of proinflammatory cytokines is reduced. Clinically relevant immunomodulation is seen is several chronic inflammatory diseases, such as diffuse panbronchiolitis, bronchiectasy, chronic sinusitis and Crohn's disease. Macrolides - especially clarithromycin - possess pronounced anti-tumor effects, anti-angiogenesis may be pivotal among them. In the case of multiple myeloma, the effect of clarithromycin monotherapy is uncertain, however, the recently inroduced BLTD protocol (clarithromycin, low-dose thalidomide and dexamethason) is reported to be one of the most effective experimental regimes, even in post-transplant relapsing or therapy-resistant disease cases.

Original languageHungarian
Pages (from-to)241-249
Number of pages9
Issue number4
Publication statusPublished - Dec 1 2002


ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gábor, M., János, J., & István, V. N. (2002). Makrolid antibiotikumok immunmodulátor és myelomaellenes hatásai. Orvoskepzes, 77(4), 241-249.